Skip to main content

Month: November 2020

Leviathan Announces Further Increase to Previously Announced Brokered Private Placement to $12.9 Million

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) — Fosterville South Exploration Ltd. (TSX-V:FSX) is pleased to announce today that, due to strong demand, Leviathan Gold Finance Ltd. (the “Company”) has agreed with Clarus Securities Inc. (“Clarus” or the “Agent”) to further increase the size of its previously announced C$9,990,000 private placement offering. Pursuant to the upsized deal terms, Clarus has agreed to sell up to 25,980,000 subscription receipts (the “Subscription Receipts”) of the Company at a price of $0.50 per Subscription Receipt to raise gross proceeds of up to $12,990,000.The net proceeds of the Offering will be used by the Company to fund the purchase price for the Avoca and Timor projects and for general working capital.The securities being offered have not, nor will they be registered under the United...

Continue reading

GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference

LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 1:50 pm EST.A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Investors section under Events & Presentations. A replay will be available soon after the live presentation.About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad...

Continue reading

Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective immediately. He succeeds Steve Bariahtaris who has served as Liquidia’s interim CFO since August 2020. Mr. Bariahtaris has agreed to provide assistance to the Company for a short period of time to support a smooth transition.“After an extensive search and thorough review of many outstanding candidates, it is with great pleasure that, today, we welcome Mike Kaseta to the Liquidia team,” said Neal Fowler, Chief Executive Officer at Liquidia. “I am confident that Mike’s financial expertise, business acumen, relevant therapeutic knowledge, as well as his extensive leadership across companies at varying stages in their lifecycle, make him a well-suited...

Continue reading

Honey Badger Files Third Quarter 2020 Financial Results, Provides 2021 Outlook

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Honey Badger Silver Inc. (TSXV: TUF) (“Honey Badger” or the “Company”) announces that it has filed its Consolidated Unaudited Financial Statements and Management Discussion and Analysis for the third quarter ended September 30, 2020, which are available under the company’s issuer profile on SEDAR at www.sedar.com.The Company also advises that, further to its press release dated October 1, 2020, the TSX Venture Exchange (“TSXV”) approved the Company’s proposed name change to “Honey Badger Silver Inc.” effective November 20, 2020 pursuant to the shareholder’s approval received at the Company’s annual general meeting on September 30, 2020 (“AGM”).Mr. Baer, Chief Executive Officer, commented, “The Company’s name change and the recent management restructure reflect our new strategic direction...

Continue reading

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignanciesRegistration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-positive lymphomas expected to begin in the first half of 2021Leading institutional investors committed a total of $105 million in private financings with ViractaCombined company expected to have approximately $120 million cash balance following the close of the mergerCompanies to host conference call today at 8:30 AM Eastern TimeSOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta Therapeutics, Inc., a privately held precision oncology company targeting virus-associated malignancies, today announced they have entered into a definitive merger...

Continue reading

Ebix and Data Glove Technologies Sign Strategic Outsourcing and Joint Venture Agreement to Offer Cloud and Infrastructure Support Services to the Insurance, Banking and Healthcare Industries

JOHNS CREEK, Ga., Nov. 30, 2020 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries today announced a strategic agreement with Data Glove Technologies, a New Jersey based firm specializing in Infrastructure, Managed Services and Cloud Services. The agreement entails various facets including outsourcing of certain back office functions and strategic joint ventures (JV) to provide cloud and infrastructure support services to the Insurance, Banking and Healthcare marketplace.The Companies announced the setting up of two joint ventures in the US and India to target the cloud and infrastructure support areas in the BFSI industry in both geographies. The JV in the US will target the US and Candian...

Continue reading

Kaloyan Radosslavov is appointed the new manager of Arco Vara Bulgaria

The Management Board of Arco Vara AS dismissed Ivaylo Mishev from the position of manager Arco Vara Group’s Bulgarian entities (Arco Vara Bulgaria EOOD, Iztok Parkside EOOD, Arco Invest EOOD, Arco Lozen EOOD, Arco Manastirski EOOD) and elected as new manager Kaloyan Radosslavov. The Management Agreement with the new manager has been concluded for 3 years.Kaloyan Radosslavov joined the team of Arco Vara in 2018 and in a short period of time successfully turned around the Madrid project into a profitable enterprise for the group. The main responsibilities before the new manager will be to complete all ongoing projects in Bulgaria, initiate new developments, diversify the real estate portfolio and increase the overall profitability of the Bulgarian arm of the group.Prior to joining Arco Vara, Kaloyan worked as a lawyer in New York, USA....

Continue reading

Kaloyan Radosslavov määratakse Arco Vara Bulgaaria uueks juhatajaks

Arco Vara AS-i juhatus vabastas Ivaylo Mishevi Arco Vara grupi Bulgaaria üksuste (Arco Vara Bulgaria EOOD, Iztok Parkside EOOD, Arco Invest EOOD, Arco Lozen EOOD, Arco Manastirski EOOD) juhataja ametikohalt ning valis uueks juhatajaks Kaloyan Radosslavovi. Juhtimise leping sõlmiti uue juhatajaga 3 aastaks.Kaloyan Radosslavov liitus Arco Vara meeskonnaga 2018. aastal ning on edukalt lühikese ajaga muutnud Madridi projekti grupi tulutoovaks ettevõtmiseks. Uue juhataja peamised ülesanded on kõigi poolikute projektide lõpetamine Bulgaarias, uute arenduste algatamine, kinnisvaraportfelli mitmekesistamine ning grupi Bulgaaria haru üldise kasumlikkuse suurendamine.Enne Arco Varaga liitumist töötas Kaloyan New Yorgis, USA-s advokaadina. Ta lõpetas Fordhami ülikooli New Yorgis, USA-s, saades õigusteaduste doktorikraadi (JD) ja ärijuhtimise magistrikraadi...

Continue reading

Interim Results for the Period Ended September 30, 2020

Good performance from projects and operationsIain Ross, CEO, Golar LNG, said:“Golar is pleased to report Q3 operating revenues of $95.2 million and adjusted EBITDA1 of $57.3 million, driven by a tenth consecutive quarter of uninterrupted commercial uptime in FLNG. Q3 TCE1 for the fleet at $39,100/day is above prior guidance of $35,000/day and driven by a higher year on year utilization of 80% for the quarter. TCE1 from the TFDE1 vessels excluding dry-dock days amounted to $43,800 for the quarter.We concluded the force majeure event with BP on the Gimi FLNG project, which resulted in an anticipated delay of 11 months to the project. All other terms of the 20 year lease and operating agreement remained unchanged. The project has ramped up manning levels to pre-lockdown numbers and remains on track to the new dates and with no material...

Continue reading

Iovance Biotherapeutics to Present at Upcoming Conferences in December

SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November:Piper Sandler 32nd Annual Virtual Healthcare Conference | December 1-3, 2020Date/Time: presentation available at http://ir.iovance.comCellular Immunotherapies for Solid Tumors Summit | December 1-3, 2020Presentation Title: Clinical Success of TIL Technology Platform in Multiple Solid TumorsDate/Time: Thursday, Dec. 3 at 2:10 pm ET at www.solid-tumors-summit.comLive and archived webcasts of investor conference presentations will be available in the Investors section of the Iovance website at http://ir.iovance.com.About Iovance Biotherapeutics, Inc.Iovance...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.